Prucalopride
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Prucalopride and local guidelines before prescribing.
Prokinetic
Mechanism
5-HT4 agonist prokinetic.
Uses
Chronic constipation in women when laxatives fail.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Headache, nausea, diarrhoea.
Interactions
Few.
Contraindications and cautions
GI obstruction, IBD
Monitoring
Bowel function
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
Reduce dose if CrCl below 30
Overdose and reversal
Supportive
Special advice
Review after 4 weeks.
More from the textbook: uses, cautions and other points
- Serotonin (5-HT) | Enterochromaffin cells (most of the body's 5-HT) | Motility, secretion, nausea | Carcinoid syndrome; ondansetron; prucalopride
Gastroenterology: Anatomy Physiology Pharmacology - Prokinetic / secretagogue | Prucalopride (5-HT4 agonist), linaclotide | Increase colonic movement or fluid secretion | Chronic constipation and IBS with constipation not helped by other laxatives (specialist or after 6–12 months)
Gastroenterology: Anatomy Physiology Pharmacology - If at least 2 laxatives have failed for 6 months: Prucalopride (a prokinetic) or linaclotide.
Gastroenterology: Bowel Disorders - Prucalopride | Chronic constipation after 2 or more laxatives fail for 6 months.
Gastroenterology: Bowel Disorders
Where it is discussed in the book
- Gastroenterology: Anatomy Physiology Pharmacology (2 mentions)
- Gastroenterology: Bowel Disorders (2 mentions)